Progenics Pharmaceuticals Earnings: Everything You Must Know Now

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) had a loss and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Progenics Pharmaceuticals Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $-0.22 in the quarter versus EPS of $-0.39 in the year-earlier quarter.

Revenue: Decreased 0% to $2.23 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Progenics Pharmaceuticals Inc. reported adjusted EPS loss of $0.22 per share. By that measure, the company missed the mean analyst estimate of $-0.19. It beat the average revenue estimate of $1.71 million.

Quoting Management: There was no comment from the management.

Key Stats (on next page)…

Revenue decreased 74.92% from $8.89 million in the previous quarter. EPS decreased to $-0.22 in the quarter versus EPS of $-0.01 in the previous quarter.

Looking Forward: Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a loss of $0.25 to a loss $0.2. For the current year, the average estimate has moved up from a loss of $1 to a loss of $0.79 over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)